ndtvprofit18d
Zydus Lifesciences' Usnoflast Gets FDA's Orphan Drug Status
Zydus Lifesciences Ltd. said on Wednesday that the US Food and Drug Administration granted its underdevelopment drug Usnoflast the orphan drug designation, according to an exchange filing on Wednesday ...
Indiatimes18d
Zydus receives USFDA Orphan Drug Designation for Usnoflast to treat ALS
“This Orphan Drug Designation from the USFDA underlines the urgent need to develop Usnoflast to address Amyotrophic Lateral Sclerosis (ALS), which is a fatal neurodegenerative disease," said Zydus' ...
Pharmaceutical Technology20d
Saroglitazar by Zydus Therapeutics for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase II drugs for ...
Business Standard20d
Zydus Life up 2% on USFDA nod for Phase II(b) clinical trial for Usnoflast
Zydus Life share price: Pharmaceutical company Zydus Life shares rose up to 1.93 per cent to hit an intraday high of Rs 1,013.35 per share on Monday, January 20, 2025. The rise in the Zydus Life share ...
moneycontrol.com21d
Stocks to Watch Today: Wipro, Tech Mahindra, Kotak Bank, RBL Bank, Gland Pharma, Zydus Life, Ashapura Minechem, Laxmi Dental in focus on 20 January
One 97 Communications Paytm, Zomato, APL Apollo Tubes, Central Bank of India, Dixon Technologies, IDBI Bank, Indian Overseas Bank, Indian Railway Finance Corporation, ICICI Securities, Jammu ...
moneycontrol.com21d
Stocks to Watch Today: Wipro, Tech Mahindra, Kotak Bank, RBL Bank, Gland Pharma, Zydus Life, Ashapura Minechem, Laxmi Dental in focus on 20 January
Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, order wins and acquisitions, here’s a quick look at which stocks will be ...
clinicaltrialsarena21d
FDA approves Zydus’ Phase IIb trial of Usnoflast for ALS treatment
Credit: David Herraez Calzada / Shutterstock. The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 ...
Cancer Therapy Advisor21d
Adjuvant T-DM1 Provides Long-Term Benefits Over Trastuzumab in HER2+ Breast Cancer
The patients were randomly assigned to receive adjuvant treatment with T-DM1 at 3.6 mg/kg (n=743) or trastuzumab at 6 mg/kg (n=743) every 3 weeks for 14 cycles. Baseline characteristics were ...
Business Standard21d
Zydus Lifesciences
Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture its generic version of Paliperidone extended-release tablets, used to treat ...
Pharmaceutical Technology21d
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs ...
Daily21d
Zydus Lifesciences gets USFDA nod to conduct Phase II(b) clinical trial for Usnoflast for Amyotrophic Lateral Sclerosis
Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 ...